432 related articles for article (PubMed ID: 30456712)
1. Neuronopathic Gaucher disease presenting with microcytic hypochromic anemia.
Kim EA; Lim YT; Hah JO; Sohn YB; Kim YK; Choi JH; Kim SY; Jang KM; Ahn J; Lee JM
Int J Hematol; 2019 Mar; 109(3):361-365. PubMed ID: 30456712
[TBL] [Abstract][Full Text] [Related]
2. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.
El-Beshlawy A; Tylki-Szymanska A; Vellodi A; Belmatoug N; Grabowski GA; Kolodny EH; Batista JL; Cox GF; Mistry PK
Mol Genet Metab; 2017; 120(1-2):47-56. PubMed ID: 28040394
[TBL] [Abstract][Full Text] [Related]
3. Velaglucerase alfa for the management of type 1 Gaucher disease.
Morris JL
Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
[TBL] [Abstract][Full Text] [Related]
4. A novel mutation causing type 1 Gaucher disease found in a Japanese patient with gastric cancer: A case report.
Hosoba S; Kito K; Teramoto Y; Adachi K; Nakanishi R; Asai A; Iwasa M; Nishimura R; Moritani S; Kawahara M; Minamiguchi H; Nanba E; Kushima R; Andoh A
Medicine (Baltimore); 2018 Jul; 97(27):e11361. PubMed ID: 29979419
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy in a patient with chronic neuronopathic Gaucher disease: a case report.
Ceravolo F; Grisolia M; Sestito S; Falvo F; Moricca MT; Concolino D
J Med Case Rep; 2017 Jan; 11(1):19. PubMed ID: 28103924
[TBL] [Abstract][Full Text] [Related]
6. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
Duan YL; Zhang YH; Zang Y; Shi HP; Zhang WM; Hu YM
Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
[TBL] [Abstract][Full Text] [Related]
7. Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease.
Pastores GM
Curr Opin Investig Drugs; 2010 Apr; 11(4):472-8. PubMed ID: 20336596
[TBL] [Abstract][Full Text] [Related]
8. A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase.
Pastores GM; Petakov M; Giraldo P; Rosenbaum H; Szer J; Deegan PB; Amato DJ; Mengel E; Tan ES; Chertkoff R; Brill-Almon E; Zimran A
Blood Cells Mol Dis; 2014 Dec; 53(4):253-60. PubMed ID: 24950666
[TBL] [Abstract][Full Text] [Related]
9. Enzyme replacement therapy for Gaucher disease in Australia.
Goldblatt J; Szer J; Fletcher JM; McGill J; Rowell JA; Wilson M
Intern Med J; 2005 Mar; 35(3):156-61. PubMed ID: 15737135
[TBL] [Abstract][Full Text] [Related]
10. [High dose of enzyme replacement therapy was successful for the pulmonary involvement in a case of type 2 Gaucher disease].
Arai N; Uematsu M; Abe Y; Fukuyo N; Wakusawa K; Kikuchi A; Sakamoto O; Ohura T; Tsuchiya S
No To Hattatsu; 2010 Jan; 42(1):45-9. PubMed ID: 23858612
[TBL] [Abstract][Full Text] [Related]
11. Three mutations of adult type 1 Gaucher disease found in a Chinese patient: A case report.
Du X; Ding Q; Chen Q; Guo P; Wang Q
Medicine (Baltimore); 2018 Nov; 97(47):e13161. PubMed ID: 30461613
[TBL] [Abstract][Full Text] [Related]
12. The appearance of newly identified intraocular lesions in Gaucher disease type 3 despite long-term glucocerebrosidase replacement therapy.
Sawicka-Gutaj N; Machaczka M; Kulińska-Niedziela I; Bernardczyk-Meller J; Gutaj P; Sowiński J; Ruchała M
Ups J Med Sci; 2016 Aug; 121(3):192-5. PubMed ID: 27064303
[TBL] [Abstract][Full Text] [Related]
13. Enzyme replacement therapy with imiglucerase in a Taiwanese child with type 1 Gaucher disease.
Lin HY; Lin SP; Chuang CK; Wraith JE
J Chin Med Assoc; 2006 May; 69(5):228-32. PubMed ID: 16835986
[TBL] [Abstract][Full Text] [Related]
14. Pediatric Gaucher disease type I and mild growth hormone deficiency: a new feature?
Biasucci G; Manfredi P
J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S51-4. PubMed ID: 20049531
[TBL] [Abstract][Full Text] [Related]
15. Glucose-6-phosphate dehydrogenase deficiency with coinherited Gaucher disease: A rare association.
Parakh N; Sharma K; Sharma S; Chatterjee P; Singh V
Indian J Pathol Microbiol; 2024 Apr; 67(2):449-451. PubMed ID: 38391334
[TBL] [Abstract][Full Text] [Related]
16. Value of plasma chitotriosidase to assess non-neuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapy.
van Dussen L; Hendriks EJ; Groener JE; Boot RG; Hollak CE; Aerts JM
J Inherit Metab Dis; 2014 Nov; 37(6):991-1001. PubMed ID: 24831585
[TBL] [Abstract][Full Text] [Related]
17. Improvement In Symptoms Of Gaucher's Disease By Enzyme Replacement Therapy.
Mazher W; Ali J; Abubakar S; Basar S; Murtaza G
J Ayub Med Coll Abbottabad; 2018; 30(3):479-481. PubMed ID: 30465391
[TBL] [Abstract][Full Text] [Related]
18. Clinical-genetic characteristics and treatment outcomes of Turkish children with Gaucher disease type 1 and type 3: A sixteen year single-center experience.
Gumus E; Karhan AN; Hizarcioglu-Gulsen H; Demir H; Ozen H; Saltik Temizel IN; Dokmeci Emre S; Yuce A
Eur J Med Genet; 2021 Nov; 64(11):104339. PubMed ID: 34500086
[TBL] [Abstract][Full Text] [Related]
19. Outcome of early-treated type III Gaucher disease patients.
Lee NC; Chien YH; Wong SL; Sheen JM; Tsai FJ; Peng SF; Leung JH; Chao MC; Shun CT; Hwu WL
Blood Cells Mol Dis; 2014 Sep; 53(3):105-9. PubMed ID: 24984925
[TBL] [Abstract][Full Text] [Related]
20. Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment.
Weinreb NJ; Camelo JS; Charrow J; McClain MR; Mistry P; Belmatoug N;
Mol Genet Metab; 2021 Feb; 132(2):100-111. PubMed ID: 33485799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
